Disclosed Amino Acid Sequence Derived From Virus Patents (Class 424/186.1)
-
Patent number: 9764025Abstract: Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (IBV). The methods typically include passing a heterogeneous attenuated population of IBV in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of IBV in embryonated chicken eggs (ECE) in order to obtain passaged attenuated population of IBV. Also disclosed are passaged attenuated populations of IBV in which the populations display a desired degree of homogeneity. Also disclosed are vaccines comprising the passaged attenuated populations of IBV and methods of vaccination comprising administering the disclosed vaccines.Type: GrantFiled: October 20, 2015Date of Patent: September 19, 2017Assignee: Auburn UniversityInventor: Haroldo E. Toro
-
Patent number: 9717783Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.Type: GrantFiled: July 19, 2013Date of Patent: August 1, 2017Assignee: STC.UNMInventors: Bryce Chackerian, David S. Peabody, Ebenezer Tumban
-
Patent number: 9687543Abstract: Provided herein are embodiments relating to porcine reproductive and respiratory syndrome (PRRS) virus, compositions comprising the virus, and methods of using the virus. The virus may be used to immunize a mammal, including swine. Methods for generating an immune response against PRRS virus in swine by administering a composition comprising the virus are provided.Type: GrantFiled: September 22, 2015Date of Patent: June 27, 2017Inventors: Federico Zuckermann, Gabriela Calzada-Nova, William Schnitzlein
-
Patent number: 9657064Abstract: The present invention relates to a short cell penetrating peptide derived from the Epstein-Barr virus basic leucine zipper transcriptional activator (ZEBRA), optionally linked to a cargo molecule. It also relates to a complex comprising the cell penetrating peptide and a cargo molecule, as well as cells loaded with the complex and the use thereof in therapy and diagnosis.Type: GrantFiled: September 12, 2013Date of Patent: May 23, 2017Assignees: LES HOPITAUX UNIVERSITAIRES DE GENEVE, UNIVERSITE DE GENEVEInventors: Madiha Derouazi, Paul Walker, Pierre-Yves Dietrich
-
Patent number: 9644022Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.Type: GrantFiled: November 30, 2010Date of Patent: May 9, 2017Assignee: Ablynx N.V.Inventors: Erik Depla, Catelijne Stortelers
-
Patent number: 9636389Abstract: The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and Lawsonia intracellularis (L. intracellularis) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) and L. intracellularis associated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by L. intracellularis, or a method for reduction of clinical symptoms caused by or associated with a PCV2 and L. intracellularis infection, comprising the step of administering an effective amount of PCV2 antigen and L. intracellularis antigen to an animal in need of such treatment.Type: GrantFiled: July 28, 2015Date of Patent: May 2, 2017Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Vicky Fachinger, Knut Elbers
-
Patent number: 9624273Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. Highly effective vaccines and immunogenic compositions against HSV-2 which can be used therapeutically or prophylactically, are described.Type: GrantFiled: November 21, 2012Date of Patent: April 18, 2017Assignee: Genocea Biosciences, Inc.Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne
-
Patent number: 9623103Abstract: The invention provides the discovery and characterization of a novel arterivirus protein (nsp2TF), whose expression is dependent on ?2 ribosomal frameshifting at a site located in the nsp2 coding region. The coding region for the unique TF domain of nsp2TF overlaps the part of ORF1a that encodes the transmembrane region of nsp2 in arteriviruses, including PRRSV, LDV and SHFV. Mutations affecting the expression of nsp2TF impair PRRSV replication and result in a smaller plaque phenotype. Provided herein are arteriviruses that display reduced translation of nsp2TF and/or altered translation of one or more downstream products, arteriviruses in which nsp2TF function is reduced and/or absent, and vaccines comprising said arteriviruses. Also provided herein are diagnostic methods, methods for identifying compounds that inhibit ?2 frameshifting, and gene expression tools for eukaryotic systems utilizing ?2 frameshifting.Type: GrantFiled: July 18, 2013Date of Patent: April 18, 2017Assignees: South Dakota Board of Regents, Cambridge Enterprise Limited, Academisch Ziekenhuis Leiden, University College CorkInventors: Ying Fang, Eric John Snijder, Andrew E. Firth, John F. Atkins, Emma Elisabeth Treffers, Ali Tas, Yanhua Li
-
Patent number: 9580481Abstract: The present invention provides compositions relating to viral capsomeres which comprise foreign immunogenic sequences for use in pharmaceutical compositions and methods of producing such compositions, and related isolated or purified protein and nucleic acid molecules, vectors, host cells, compositions, and methods of use to augment an immune response, immunize an animal and prophylactically or therapeutically treat a disease, disorder or condition. The viral capsomere may be derived from a polyomavirus and comprise an immunogen of interest at the N-terminus and further at the C-terminus and/or at one or more exposed loops of the capsomere.Type: GrantFiled: August 13, 2012Date of Patent: February 28, 2017Assignee: University of QueenslandInventors: Anton Peter Jacob Middelberg, Linda Hwee-Lin Lua
-
Patent number: 9579374Abstract: Certain embodiments of the present invention include a method for rapidly designing pharmaceutical preparations for preventing viral infection that have adapted to growth in various culturing systems but maintain antigenic similarity to the original virus. The method may include serial passaging a plurality of instances of a targeted virus strain from an infected first animal in respective droplets in second animal cells, in parallel synthesizing antibodies that neutralize the targeted virus strain in a third animal, and selecting the second animal cell-adapted viral lineages that are neutralized by the antibodies to identify second animal cell-adapted viral lineages having antigenic similarity to the targeted virus strain.Type: GrantFiled: December 3, 2014Date of Patent: February 28, 2017Assignee: The Johns Hopkins UniversityInventors: Jeffrey S. Lin, Andrew S. Pekosz, Andrew B. Feldman
-
Patent number: 9579376Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: June 1, 2015Date of Patent: February 28, 2017Assignees: UNIVERSITY OF WASHINGTON, FRED HUTCHINSON CANCER RESEARCH CENTERInventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
-
Patent number: 9573979Abstract: The invention relates to a modified VP1-capsid protein of parvovirus B19 having a reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SeqID 1.Type: GrantFiled: September 23, 2005Date of Patent: February 21, 2017Inventors: Susanne Modrow, Torsten Lowin, Markus Mobs, Michael Broker
-
Patent number: 9572877Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.Type: GrantFiled: December 17, 2011Date of Patent: February 21, 2017Assignee: EYEGENE, INC.Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won II Yoo
-
Patent number: 9566324Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.Type: GrantFiled: November 9, 2011Date of Patent: February 14, 2017Assignee: Zoetis Services LLCInventors: Jay Gregory Calvert, David Ewell Slade, Siao-Kun W. Welch
-
Patent number: 9555093Abstract: The present invention relates to a universal H5N1 vaccine. More specifically, the present invention relates to the identification of three H5N1 strains which cover the entire variants in the neutralizing epitopes of hemagglutinin among most H5N1 lineages. The present invention further relates a universal H5N1 vaccine that comprises the three H5N1 strains or that comprises hemagglutinin peptides of each of these three strains.Type: GrantFiled: February 9, 2011Date of Patent: January 31, 2017Assignee: TEMASEK LIFE SCIENCES LABORATORY LIMITEDInventors: Prabakaran Mookkan, Fang He, Hwei-Sing Jimmy Kwang
-
Patent number: 9555098Abstract: This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.Type: GrantFiled: September 10, 2013Date of Patent: January 31, 2017Assignee: MERIAL INC.Inventor: Francois Xavier Le Gros
-
Patent number: 9550812Abstract: The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.Type: GrantFiled: August 31, 2012Date of Patent: January 24, 2017Assignee: Ceva Sante AnimaleInventors: Zoltan Penzes, Anna Kollar, Marianna Ivok
-
Patent number: 9546375Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of a novel influenza HA protein in plants and its purification The invention is also directed towards a VLP comprising influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding improved influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.Type: GrantFiled: July 15, 2009Date of Patent: January 17, 2017Assignee: MEDICAGO INC.Inventors: Manon Couture, Louis-Philippe Vezina, Nathalie Landry
-
Patent number: 9533038Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: GrantFiled: April 30, 2015Date of Patent: January 3, 2017Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Christopher C. Broder, Katharine N. Bossart
-
Patent number: 9533057Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.Type: GrantFiled: February 8, 2011Date of Patent: January 3, 2017Assignee: STC.UNMInventors: Bryce Chackerian, David S. Peabody
-
Patent number: 9505808Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.Type: GrantFiled: October 2, 2014Date of Patent: November 29, 2016Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
-
Patent number: 9499590Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.Type: GrantFiled: September 8, 2014Date of Patent: November 22, 2016Assignee: MedImmune, LLCInventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, JoAnn Suzich
-
Patent number: 9470686Abstract: An in vitro method that allows detection of hepatitis C by detecting hepatitis C virus (HCV) core protein and antibodies to HCV core protein (anti-core antibodies) in a single assay is provided. Cross-reactivity is eliminated in the method preferably by utilizing short peptides, each of which has an amino acid sequence that corresponds to an immunodominant region of the native core protein but which does not wholly encompass the epitope bound by the antibodies utilized in the method. The method can be used to detect the presence of HCV in a subject, and/or to determine the suitability of donor blood or blood products for transfusion purposes. Also provided are diagnostic kits for carrying out the method and a process for selecting suitable capture peptides and monoclonal antibodies for use in the combination method.Type: GrantFiled: September 9, 2014Date of Patent: October 18, 2016Assignee: ABBOTT LABORATORIESInventors: Brian C. Rodgers, Graham J. Burch
-
Patent number: 9439935Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.Type: GrantFiled: January 24, 2014Date of Patent: September 13, 2016Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
-
Patent number: 9408905Abstract: The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.Type: GrantFiled: July 1, 2014Date of Patent: August 9, 2016Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Feng Yao
-
Patent number: 9394369Abstract: The disclosure relates to immunizing agents and devices.Type: GrantFiled: January 3, 2012Date of Patent: July 19, 2016Assignee: The Regents of the University of CaliforniaInventors: Michael J. Sailor, Stephen M. Hedrick, Lou Gu, Laura Ruff, Zhengtao Qin
-
Patent number: 9388218Abstract: This invention provides kits, devices, and methods for the detection of antibodies that recognize one or more proteins and/or antigens from porcine reproductive and respiratory syndrome virus (PRRSV). The antibodies may be in a biological fluid of a PRRSV infected or at risk subject. The invention may be advantageously applied to both the diagnosis and prevention of PRRSV infection.Type: GrantFiled: July 16, 2010Date of Patent: July 12, 2016Assignee: Regents of the University of MinnesotaInventor: Han-Soo Joo
-
Patent number: 9387238Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e.Type: GrantFiled: June 18, 2009Date of Patent: July 12, 2016Assignee: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura
-
Patent number: 9352031Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.Type: GrantFiled: February 18, 2011Date of Patent: May 31, 2016Assignee: TechnoVax, Inc.Inventors: Jose M. Galarza, George R. Martin
-
Patent number: 9345782Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: GrantFiled: October 26, 2012Date of Patent: May 24, 2016Assignee: FREDAX ABInventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Patent number: 9345760Abstract: The present invention provides bivalent oral vaccines against infectious pancreatic necrosis virus (IPNV) and infectious salmon anemia virus (ISAV). Yeast cells comprise an expression vector comprising (i) a polynucleotide sequence encoding a VP2 capsid protein of IPNV and (ii) a polynucleotide sequence encoding one or more antigenic epitopes of hemaglutinin of ISAV. The yeast cells express sub-viral particles (SVP) comprising a VP2 capsid protein of IPNV and one or more antigenic epitopes of hemaglutinin of ISAV. The yeast cells and SVP may be administered in an effective amount to increase the amount of antibodies against IPNV and ISAV in the fish, preferably Salmonidae. The yeast cells and SVP may be in the form of fish food for administering to the fish orally.Type: GrantFiled: September 7, 2012Date of Patent: May 24, 2016Assignee: Advanced Bionutrition CorporationInventor: Arun K. Dhar
-
Patent number: 9334309Abstract: The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.Type: GrantFiled: January 24, 2014Date of Patent: May 10, 2016Assignee: Massachusetts Institute of TechnologyInventors: Ram Sasisekharan, Karthik Viswanathan, Venkataramanan Soundararajan, S. Raguram, Viswanathan Sasisekharan, Vidya Subramanian
-
Patent number: 9249192Abstract: The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of Torque teno sus virus (TTsuV). The present invention also provides methods for diagnosing TTsuV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies which indicate infections TTsuV1, TTsuV2, and individual TTsuV1 genotypes.Type: GrantFiled: March 15, 2013Date of Patent: February 2, 2016Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Xiang-Jin Meng, Yaowei Huang
-
Patent number: 9249395Abstract: The present invention concerns replicons of pestiviruses, in particular replicons of swine fever virus, engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon of the invention contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins E1, E2, Ems or C protein, and consequently cannot generate infectious virus particles. Particular replicons are generated with a mutated gene encoding a modified Npro protein that no longer controls the cell interferon-induction pathway. Another particular replicon lacks the genes encoding all the structural proteins, the p7 protein and the NS2 protein, and has cytopathogenic properties in transduced cells.Type: GrantFiled: May 30, 2009Date of Patent: February 2, 2016Assignee: INSTITUT FUR VIRUSKRANKHEITEN UND IMMUNPROPHYLAXEInventors: Jon Duri Tratschin, Nicolas Ruggli, Kenneth Charles McCullough
-
Patent number: 9193769Abstract: The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles.Type: GrantFiled: February 13, 2014Date of Patent: November 24, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Chiorini, Michael Schmidt, Ioannis Bossis, Giovanni Di Pasquale
-
Patent number: 9187731Abstract: The present invention relates to the field of attenuated live viruses useful as vaccine or medicament for preventing or treating Porcine Reproductive and Respiratory Syndrome (PRRS) in swine, and is based on the surprising finding of a PRRS virus which is able to induce the interferon type I response of a cell infected by said virus. In one embodiment, the PRRS virus according to the invention is a PRRS virus mutant comprising, in comparison with the genome of a wild type strain, a mutation in the gene encoding the non structural protein 1 (nsp1) of said virus.Type: GrantFiled: July 26, 2012Date of Patent: November 17, 2015Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Andreas Gallei
-
Patent number: 9149503Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.Type: GrantFiled: April 12, 2010Date of Patent: October 6, 2015Assignee: The Johns Hopkins UniversityInventors: Richard B. S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
-
Patent number: 9138470Abstract: Embodiments of the invention are directed to methods and compositions for generating an antibody response against HPV epitopes using multi-component vaccines. One such multi-component vaccine requires a T cell helper component and a toll-like receptor (TLR) agonist. In one embodiment, the inventors described a lipopeptide composition comprising an HPV L2 epitope.Type: GrantFiled: November 3, 2008Date of Patent: September 22, 2015Assignee: The Johns Hopkins UniversityInventors: Richard B. S. Roden, Ratish Gambhira, Hannah H. Alphs
-
Patent number: 9119834Abstract: A high level replication fowl adenovirus (FAdV) isolate capable of reaching a viral titer of at least 3 log 10 is described. Said FAdV is a non-pathogenic strain of fowl adenovirus serotype 4, identified as FAdV-4 ON1. Additionally, the present disclosure also provides a viral vector comprising the fowl adenovirus, which has inserted an exogenous nucleotide sequence coding for at least one antigenic site of a disease of concern, as well as a method for obtaining said viral vector and an immunogenic composition comprising the same.Type: GrantFiled: March 16, 2012Date of Patent: September 1, 2015Assignee: University of GuelphInventors: Éva Nagy, Bryan Griffin, Helena Grgic, Davor Ojkic
-
Patent number: 9090664Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.Type: GrantFiled: July 26, 2013Date of Patent: July 28, 2015Assignee: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Patent number: 9051361Abstract: Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods.Type: GrantFiled: August 17, 2010Date of Patent: June 9, 2015Assignee: National Health Research InstitutesInventors: Pele Choi-Sing Chong, Chia-Chyi Liu, Meng-Shin Kuo, Ray Jui-Yuan Chang
-
Publication number: 20150147329Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.Type: ApplicationFiled: July 25, 2014Publication date: May 28, 2015Inventors: Rahul Raman, Xiaoying Koh, Karthik Viswanathan, Ram Sasisekharan, Aarthi Chandrasekaran
-
Publication number: 20150140103Abstract: The present invention relates to a nucleic acid for vaccine that has undergone codon optimization for expression in Bombyx mori, a vector comprising the nucleic acid, Bombyx mori comprising the vector, and a method for producing a vaccine in which they are used.Type: ApplicationFiled: July 23, 2013Publication date: May 21, 2015Inventors: Kazumichi Kuroda, Shigeo Sugita, Kuniaki Nerome, Reiko Nerome
-
Publication number: 20150140025Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.Type: ApplicationFiled: May 16, 2013Publication date: May 21, 2015Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
-
Publication number: 20150140065Abstract: The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of influenza virus and other infectious diseases. Compositions containing the same, methods for producing the same, and methods for using the same are also disclosed, wherein the peptide constructs have the formula P1-x-P2, where P2 is a peptide associated with an infectious agent and P1 is a peptide that will bind to a class of immune cells, such as dendritic cells. The peptide construct can cause the maturation of immature dendritic cells to a more mature state. The peptide construct or the more mature dendritic cell can be administered to a subject to modulate or initiate an immune response against an infectious agent.Type: ApplicationFiled: May 24, 2012Publication date: May 21, 2015Applicant: CEL-SCI CORPORATIONInventors: Daniel H. Zimmerman, Eyal Talor, Kanta Subbarao, Kobporn Boonnak
-
Patent number: 9034340Abstract: The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein L1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein L1 of human papilloma virus in a yeast cell. The present invention further discloses the use of said immunogenic macromolecule and a composition comprising said immunogenic macromolecule.Type: GrantFiled: June 5, 2014Date of Patent: May 19, 2015Assignee: Shanghai Zerun Biotechnology Co., Ltd.Inventors: Goaxia Zhang, Qiong Shen, Jianqiang Lei, Jingyu Yuan, Menghua Zhang, Qianli Zhang, Yinghua Xiong, Roger Wei, Ke Wu
-
Publication number: 20150132330Abstract: Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.Type: ApplicationFiled: September 19, 2012Publication date: May 14, 2015Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Natalie Pica, Dirk Eggink, Rafael A. Medina-Silva, Rong Hai
-
Publication number: 20150132331Abstract: Vaccine compositions and methods of producing and using the same are provided, which compositions comprise a modified HA stem domain in a trimeric configuration.Type: ApplicationFiled: May 23, 2013Publication date: May 14, 2015Inventors: Yuan Lu, James R. Swartz
-
Publication number: 20150125384Abstract: Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.Type: ApplicationFiled: November 10, 2014Publication date: May 7, 2015Inventors: Ira S. Mellman, Tarek M. Fahmy, William Mark Saltzman, Michael J. Caplan
-
Patent number: RE46453Abstract: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.Type: GrantFiled: February 25, 2015Date of Patent: June 27, 2017Assignees: POSTECH FOUNDATION, GENEXINE, INC.Inventors: Young Chul Sung, Hyun Tak Jin, Sang Hwan Seo, Sang Hoon Park, Je-In Youn